Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DiaMedica Therapeutics Inc. - Common Stock (NQ:DMAC)

5.974 -0.076 (-1.26%)
Streaming Delayed Price Updated: 11:17 AM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DiaMedica Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
Recap: DiaMedica Therapeutics Q4 Earnings ↗
 
Via Benzinga
News headline image
Earnings Outlook For DiaMedica Therapeutics ↗
 
Via Benzinga
News headline image
DiaMedica Therapeutics Announces $11.8 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q1 2024 ↗
DMAC stock results show that DiaMedica Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023 ↗
DMAC stock results show that DiaMedica Therapeutics met analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 13, 2023 ↗
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. 
Via Benzinga
News headline image
DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
Pre-market stock movers are a hot topic on Wednesday and we're offering all the details that investors need to know about this morning. 
Via InvestorPlace
News headline image
DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
Three (3) Stocks Under $10 That Insiders Are Buying
These small-cap names provide an opportunity that insiders are buying including deep value, growth, new technology, and AI. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
DiaMedica Therapeutics Announces Closing of $37.5 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023 ↗
 
Via Benzinga
News headline image
DiaMedica Raises $37.5M Via Equity Offering, Aiding Development Activities For DM199 ↗
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) has entered into an agreement with accredited investors that have agreed to provide up to $37.5 million in gross proceeds through a  
Via Benzinga
News headline image
DiaMedica Therapeutics Announces $37.5 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.